Novavax Appoints James Robinson Vice President of Technical and Quality Operations
ROCKVILLE, Md., March 14 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) has appointed James M. Robinson Vice President of Technical and Quality Operations, the company said today. Robinson, age 46, joins Novavax from Sanofi Pasteur, a division of Sanofi Aventis Group, where he most recently served as Vice President of Industrial Operations.
In that capacity, Robinson was responsible for all aspects of Sanofi's Swiftwater, Pa., site's sterile manufacturing operations including quality control, production planning, engineering, warehousing and strategic planning. He oversaw a combined group of 1,000, and in eight years at the facility increased production of various products by up to three-fold through improved processes and facility utilization.
"I am delighted to welcome Jim to our management team," said Novavax President and Chief Executive Officer Dr. Rahul Singhvi. "He joins Novavax at an opportune time as we begin scaling up our innovative manufacturing system. Jim's leadership will be critical in translating our vision of dovetailing our virus-like particle vaccine platform with our portable, disposable manufacturing technology to revolutionize vaccine development and production."
Throughout his career, Robinson has been responsible for the production of a broad variety of vaccines for both humans and animals. "Jim has the breadth of experience in project, product and people management that is essential for our successful transition to a premier vaccine company dedicated to meeting unmet medical needs," Dr. Singhvi said.
"I am excited to join Novavax," Robinson said. "It is rare to find a company in the biotechnology field in which manufacturing is central to its core mission. I am eager to become part of a team dedicated to improving vaccines and the way they are produced."
A graduate of Lehigh University with both bachelor's and master's degrees in chemical engineering, Robinson began his career at G.D. Searle & Co. as a pilot plant manager in the company's NutraSweet Division. In 1986 he joined Sanofi as a vaccine production supervisor. He held various positions at Sanofi before being named vice president in 1998.
About Novavax Inc.
Novavax Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
SOURCE Novavax Inc.
CONTACT: Mariann Caprino of Novavax Inc.,